Home
Astrid Olsnes Kittang's picture

Astrid Olsnes Kittang

Associate Professor
  • E-mailAstrid.Olsnes.Kittang@uib.no
  • Phone+47 55 58 54 11
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Journal articles
  • Tobiasson, Magnus; Kittang, Astrid Marta Olsnes. 2019. Treatment of myelodysplastic syndrome in the era of next-generation sequencing. Journal of Internal Medicine. 1-22. doi: 10.1111/joim.12893
  • Norberg, Anna; Rosén, Anna; Raaschou-Jensen, Klas; Kjeldsen, Lars; Moilanen, Jukka S.; Paulsson-Karlsson, Ylva; Baliakas, Panagiotis; Lohi, Olli; Ahmed, Aymen B; Kittang, Astrid Marta Olsnes; Larsson, Pär; Roos, Göran; Degerman, Sofie; Hultdin, Magnus. 2018. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. European Journal of Human Genetics. 26: 858-867. doi: 10.1038/s41431-018-0112-8
  • Kittang, Astrid Marta Olsnes; Kordasti, Shahram; Sand, Kristoffer; Costantini, Benedetta; Kramer, Anne Marijn; Perezabellan, Pilar; Seidl, Thomas; Rye, Kristin Paulsen; Hagen, Karen Marie; Kulasekararaj, Austin; Bruserud, Øystein; Mufti, Ghulam J. 2016. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 5:e1062208. doi: 10.1080/2162402X.2015.1062208
  • Kittang, Astrid Marta Olsnes; Sand, Kristoffer; Brenner, Annette; Rye, Kristin Paulsen; Bruserud, Øystein. 2016. The systemic profile of soluble immune mediators in patients with myelodysplastic syndromes. International Journal of Molecular Sciences. 17:1080. doi: 10.3390/ijms17071080
  • Sand, Kristoffer; Theorell, Jakob; Bruserud, Øystein; Bryceson, Yenan; Kittang, Astrid Marta Olsnes. 2016. Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes. Cancer Immunology and Immunotherapy. 65: 1135-1137. doi: 10.1007/s00262-016-1865-y
  • Jonsson, Maria Karolina; Hammenfors, Daniel; Oppegaard, Oddvar; Bruserud, Øystein; Kittang, Astrid Marta Olsnes. 2015. A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura. Blood Coagulation and Fibrinolysis. 26: 469-472. doi: 10.1097/MBC.0000000000000255
  • Tobiasson, Magnus; Dybedal, Ingunn; Holm, Mette Skov; Karimi, Mohsen; Brandefors, Lena; Garelius, Hege; Grövdal, Michael; Høgh-Dufva, Inge; Grønbæk, Kirsten; Jansson, Monika; Marcher, Vlaus Werenberg; Nilsson, Lars Håkan; Kittang, Astrid Marta Olsnes; Porwit, Anna; Saft, Leonie; Möllgård, Lars; Hellström-Lindberg, Eva. 2014. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer Journal. 4. doi: 10.1038/bcj.2014.8
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Kittang, Astrid Marta Olsnes; Tsykunova, Galina; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics. 5:13. doi: 10.1186/1868-7083-5-13
  • Reikvam, Håkon; Fredly, Hanne Kristin; Kittang, Astrid Marta Olsnes; Bruserud, Øystein. 2013. The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine-the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation. Toxins. 5: 336-362. doi: 10.3390/toxins5020336
  • Reikvam, Håkon; Kittang, Astrid Marta Olsnes; Melve, Guro Kristin; Mosevoll, Knut Anders; Bentsen, Pål Tore; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 13: 30-47. doi: 10.2174/1568009611309010030
  • Sand, Kristoffer; Rye, Kristin Paulsen; Mannsåker, Bård; Bruserud, Øystein; Kittang, Astrid Marta Olsnes. 2013. Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. Oncoimmunology. 2. 11 pages. doi: 10.4161/onci.23138
  • Bruserud, Øystein; Reikvam, Håkon; Kittang, Astrid Marta Olsnes; Ahmed, Aymen B; Tvedt, Tor Henrik Anderson; Sjo, Malvin; Hatfield, Kimberley Joanne. 2012. High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemotherapy and Pharmacology. 70: 765-782. doi: 10.1007/s00280-012-1990-z
  • Melve, Guro Kristin; Ersvær, Elisabeth; Kittang, Astrid Marta Olsnes; Bruserud, Øystein. 2011. The chemokine system. in allogeneic stem-cell transplantation: a possible therapeutic target? Expert Review of Hematology. 4: 563-576. doi: 10.1586/EHM.11.54
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Kittang, Astrid Marta Olsnes; Hovland, Randi; Bruserud, Øystein. 2011. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. Journal of Biomedicine and Biotechnology. 23 pages. doi: 10.1155/2011/104631
  • Bruserud, Øystein; Kittang, Astrid Marta Olsnes. 2010. The chemokine system in experimental and clinical hematology. Current Topics in Microbiology and Immunology. 341: 3-12. doi: 10.1007/82_2010_18
  • Kittang, Astrid Marta Olsnes; Hatfield, Kimberley Joanne; Sand, Kristoffer Evebø; Reikvam, Håkon; Bruserud, Øystein. 2010. The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications. Current Topics in Microbiology and Immunology. 341: 149-172. doi: 10.1007/82_2010_25
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Lassalle, Philippe; Kittang, Astrid Marta Olsnes; Ersvær, Elisabeth; Bruserud, Øystein. 2010. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs. 19: 169-183. doi: 10.1517/13543780903485659
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Kalland, Karl-Henning; Kittang, Astrid Marta Olsnes; Bruserud, Øystein. 2010. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 84: 239-251. doi: 10.1111/j.1600-0609.2009.01382.x
  • Sand, Kristoffer Evebø; Kittang, Astrid Marta Olsnes; Bruserud, Øystein. 2010. Circulating T Cells Derived From Patients with Low Risk Myelodysplastic Syndromes Show Altered Chemokine Receptor Expression. Blood. 116: 1637-1638.
  • Olsnes, Astrid Marta; Ersvær, Elisabeth; Ryningen, Anita; Paulsen, Kristin; Hampson, Peter; Lord, Janet M.; Gjertsen, Bjørn Tore; Kristoffersen, Einar Klæboe; Bruserud, Øystein. 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 145: 761-774. doi: 10.1111/j.1365-2141.2009.07691.x
  • Olsnes, Astrid Marta; Hatfield, Kimberley Joanne; Bruserud, Øystein. 2009. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. Balkan Union of Oncology. Journal. 14: S131-S140.
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Olsnes, Astrid Marta; Øyan, Anne Margrete; Kalland, Karl-Henning; Bruserud, Øystein. 2009. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 94: 545-545.
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Kalland, Karl-Henning; Kittang, Astrid Marta Olsnes; Bruserud, Øystein. 2009. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 84: 239-251. doi: 10.1111/j.1600-0609.2009.01382.x
  • Reikvam, Håkon; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore; Ersvær, Elisabeth; Bruserud, Øystein. 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 15: 1-41.
  • Bruserud, Øystein; Ersvær, Elisabeth; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore. 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 8: 666-675. doi: 10.2174/156800908786733496
  • Olsnes, Astrid Marta; Ersvær, Elisabeth; Ryningen, Anita; Bruserud, Øystein. 2008. Chemokine receptor expression by circulating T cells derived from acute leukemia patients with severe chemotherapy-induced cytopenia express a wide range of chemokine receptors. Haematologica. 93: 456-457.
  • Olsnes, Astrid Marta; Ryningen, Anita; Ersvær, Elisabeth; Bruserud, Øystein. 2008. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. Journal of Interferon and Cytokine Research. 28: 297-310. doi: 10.1089/jir.2007.0052
  • Bruserud, Øystein; Ryningen, Anita; Olsnes, Astrid Marta; Stordrange, Laila; Øyan, Anne Margrete; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 92: 332-341.
  • Ersvær, Elisabeth; Olsnes, Astrid Marta; Bruserud, Øystein. 2007. The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia. The Open Hematology Journal. 1: 1-14. doi: 10.2174/1874276900701010001
  • Ersvær, Elisabeth; Zhang, Jian-Ying; McCormack, Emmet Martin; Olsnes, Astrid Marta; Ånensen, Nina; Tan, Eng M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 79: 210-225. doi: 10.1111/j.1600-0609.2007.00899.x
  • Olsnes, Astrid Marta; Ersvær, Elisabeth; Bruserud, Øystein. 2007. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts: The chemokine release profile of the AML dendritic cells depends on the experimental protocol. Haematologica. 92: 485-485.
  • Olsnes, Astrid Marta; Ersvær, Elisabeth; Ryningen, Anita; Hampson, Peter; Lord, Janet M.; Bruserud, Øystein. 2007. The protein kinase C activator PEP005 increases the chemokine release in native acute myelogenous leukemia (AML) blasts. Experimental Hematology. 35: 87-87.
  • Olsnes, Astrid Marta; Motorin, Dmitri; Ryningen, Anita; Zaritskey, Andrey Y.; Bruserud, Øystein. 2006. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunology and Immunotherapy. 55: 830-840. doi: 10.1007/s00262-005-0080-z
  • Hatfield, Kimberley Joanne; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 5: 229-248.
Reports and theses
  • Kittang, Astrid Marta Olsnes. 2008. The chemokine system in acute myelogenous leukemia.

More information in national current research information system (CRIStin)